Market research
GBS GBS Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 4.5
- Dividend yield
- 0.0%
- Beta
- Not available
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
- ISIN
- US36151G1058
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 4.5
- Dividend yield
- 0.0%
- Beta
- Not available
About
About GBS Inc
GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the GBS discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 41.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 780.3.
Based on the above factors, GBS Inc gets an overall score of 1/5.